JP2023506642A5 - - Google Patents

Info

Publication number
JP2023506642A5
JP2023506642A5 JP2022537250A JP2022537250A JP2023506642A5 JP 2023506642 A5 JP2023506642 A5 JP 2023506642A5 JP 2022537250 A JP2022537250 A JP 2022537250A JP 2022537250 A JP2022537250 A JP 2022537250A JP 2023506642 A5 JP2023506642 A5 JP 2023506642A5
Authority
JP
Japan
Prior art keywords
piperidine
dione
methoxy
oxoisoindorin
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022537250A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023506642A (ja
JP7682181B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/062070 external-priority patent/WO2021124172A1/en
Publication of JP2023506642A publication Critical patent/JP2023506642A/ja
Publication of JP2023506642A5 publication Critical patent/JP2023506642A5/ja
Application granted granted Critical
Publication of JP7682181B2 publication Critical patent/JP7682181B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022537250A 2019-12-18 2020-12-16 3-(5-メトキシ-1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用 Active JP7682181B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962950048P 2019-12-18 2019-12-18
US62/950,048 2019-12-18
PCT/IB2020/062070 WO2021124172A1 (en) 2019-12-18 2020-12-16 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof

Publications (3)

Publication Number Publication Date
JP2023506642A JP2023506642A (ja) 2023-02-17
JP2023506642A5 true JP2023506642A5 (cg-RX-API-DMAC7.html) 2024-01-30
JP7682181B2 JP7682181B2 (ja) 2025-05-23

Family

ID=73856242

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022537250A Active JP7682181B2 (ja) 2019-12-18 2020-12-16 3-(5-メトキシ-1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用

Country Status (23)

Country Link
US (1) US11566022B2 (cg-RX-API-DMAC7.html)
EP (1) EP4076650B1 (cg-RX-API-DMAC7.html)
JP (1) JP7682181B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220114065A (cg-RX-API-DMAC7.html)
CN (1) CN114828959B (cg-RX-API-DMAC7.html)
AR (1) AR120773A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020410514A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022011796A2 (cg-RX-API-DMAC7.html)
CA (1) CA3164832A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022008243A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220278A (cg-RX-API-DMAC7.html)
DO (1) DOP2022000121A (cg-RX-API-DMAC7.html)
EC (1) ECSP22055267A (cg-RX-API-DMAC7.html)
ES (1) ES2980575T3 (cg-RX-API-DMAC7.html)
IL (1) IL293530A (cg-RX-API-DMAC7.html)
JO (1) JOP20220152A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022007351A (cg-RX-API-DMAC7.html)
PE (1) PE20230159A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022551482A1 (cg-RX-API-DMAC7.html)
PY (1) PY2084899A (cg-RX-API-DMAC7.html)
TW (1) TW202130631A (cg-RX-API-DMAC7.html)
UY (1) UY38986A (cg-RX-API-DMAC7.html)
WO (1) WO2021124172A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3186926A1 (en) * 2020-08-07 2022-02-10 Francis Barany Therapeutically useful cure-pro molecules for e3 ligase mediated degradation of proteins, and methods of making and using them
UY39671A (es) 2021-03-15 2022-10-31 Novartis Ag Derivados de pirazolopiridina y sus usos.
WO2022254362A1 (en) 2021-06-03 2022-12-08 Novartis Ag 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof
JP7744061B2 (ja) * 2021-07-30 2025-09-25 ヒノバ ファーマシューティカルズ インコーポレイテッド 二官能性キメラ複素環式化合物及びアンドロゲン受容体分解剤としての使用
US20240124412A1 (en) * 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN120129677A (zh) 2022-11-04 2025-06-10 百时美施贵宝公司 化合物及其用于治疗血红素病变的用途
EP4644382A4 (en) * 2022-12-27 2026-04-01 Gluetacs Therapeutics Shanghai Co Ltd ISOINDOLINONE SKELETON-BASED COMPOUND WITH SULFUR/OXYGEN SUBSTITUTED GLUTARIMIDE AND ITS USE
CN115959976A (zh) * 2022-12-30 2023-04-14 安徽诺全药业有限公司 一种甲氧基取代双环戊烷衍生物的制备方法
WO2024255810A1 (en) * 2023-06-15 2024-12-19 Hangzhou Glubio Pharmaceutical Co., Ltd Dihydropyrimidine-2, 4 (1h, 3h) -dione-containing polycyclic derivatives and pharmaceutical composition thereof, preparation method thereof and use thereof
TW202530209A (zh) * 2023-10-06 2025-08-01 美商德爾菲亞治療股份有限公司 化合物、其醫藥組合物及其使用方法
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists
WO2025137613A1 (en) * 2023-12-22 2025-06-26 Ganymede Oncology, Inc. Cycloalkylene nrf2 protein degraders
WO2026035999A1 (en) 2024-08-09 2026-02-12 Triana Biomedicines, Inc. Anaplastic lymphoma kinase (alk) degraders and uses thereof
CN120717945A (zh) * 2025-08-15 2025-09-30 泰迩生物医药泰州有限公司 一种(2r,4s)-n-boc-4-羟基哌啶-2-甲酸甲酯的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
JP2004532616A (ja) 2000-12-28 2004-10-28 ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド 二本鎖rna仲介遺伝子抑制
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
SG183257A1 (en) 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2012068512A1 (en) 2010-11-18 2012-05-24 Deuteria Pharmaceuticals Llc 3-deutero-pomalidomide
WO2012079022A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
WO2014018866A1 (en) 2012-07-27 2014-01-30 Celgene Corporation Processes for preparing isoindoline-1,3-dione compounds
US20170038387A1 (en) 2015-08-04 2017-02-09 Celgene Corporation Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
WO2017185031A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
SI3526202T1 (sl) 2016-10-11 2025-04-30 Arvinas Operations, Inc. Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
MX2019005007A (es) 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
IL266842B (en) 2016-12-01 2022-09-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
CN110753693A (zh) 2016-12-23 2020-02-04 阿尔维纳斯运营股份有限公司 Egfr蛋白水解靶向嵌合分子和相关使用方法
IL325835A (en) 2016-12-23 2026-03-01 Univ Yale Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
IL300417A (en) 2017-01-26 2023-04-01 Arvinas Operations Inc Bifunctional benzothiophene compounds, preparations containing them and their use in therapy
SG11202003415XA (en) 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
EP3676268A1 (en) 2017-10-20 2020-07-08 Dana-Farber Cancer Institute, Inc. Heterobifunctional compounds with improved specificityfor the bromodomain of brd4
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2019177902A1 (en) 2018-03-10 2019-09-19 Yale University Modulators of btk proteolysis and methods of use
CN111902141A (zh) 2018-03-26 2020-11-06 C4医药公司 用于ikaros降解的羟脑苷脂结合剂
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
CA3095912A1 (en) 2018-04-13 2019-10-17 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
CA3102212A1 (en) 2018-06-29 2020-01-02 Dana-Farber Cancer Institute, Inc. Immunomodulatory compounds
AU2019294835B2 (en) 2018-06-29 2025-04-17 Dana-Farber Cancer Institute, Inc. Ligands to cereblon (CRBN)
EP3814380A4 (en) 2018-06-29 2022-06-15 Dana Farber Cancer Institute, Inc. BISPECIFIC DEGRADATION PRODUCTS
US12030892B2 (en) 2018-06-29 2024-07-09 Dana-Farber Cancer Institute, Inc. CRBN modulators
CN113490495B (zh) 2018-12-03 2024-09-27 达纳-法伯癌症研究公司 Helios的小分子降解剂及其使用方法
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives

Similar Documents

Publication Publication Date Title
US20230346927A1 (en) COMBINATION of ATR KINASE INHIBITORS and PD-1/PD-L1 INHIBITORS
US11964953B2 (en) Substituted aminothiazoles as DGKzeta inhibitors for immune activation
JP6409081B2 (ja) 治療活性化合物およびその使用方法
CA2984259C (en) Combinations of inhibitors of irak4 with inhibitors of btk
US11304946B2 (en) 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists
US10028961B2 (en) Therapeutically active compounds and their methods of use
CA2956992C (en) 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES
JP2024521618A5 (cg-RX-API-DMAC7.html)
JP5687903B2 (ja) キヌレニン産生抑制剤
JP2017500364A5 (cg-RX-API-DMAC7.html)
JP2023525762A5 (cg-RX-API-DMAC7.html)
TW201840549A (zh) 2-雜芳基-3-氧代-2,3-二氫噠嗪-4-甲醯胺
US11660301B2 (en) Combination of ATR kinase inhibitors with PARP inhibitors
TWI803600B (zh) 新穎的三唑酮衍生物或其鹽及包含彼等之醫藥組合物
JP2013523819A5 (cg-RX-API-DMAC7.html)
US10894784B2 (en) Heteroarylbenzimidazole compounds
AU2022258751A1 (en) Phosphorus derivatives as novel sos1 inhibitors
US20240174683A1 (en) Map4k1 inhibitors
WO2018153971A1 (en) Combination of atr kinase inhibitors
US9695198B2 (en) Factor IXa inhibitors
US20240383875A1 (en) Benzimidazole Pyridine Derivatives
US20230405015A1 (en) Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma
JP2023550902A5 (cg-RX-API-DMAC7.html)
RU2023130418A (ru) Гетероциклические соединения
EA048085B1 (ru) Замещенные аминотиазолы в качестве ингибиторов dgkzeta для иммунной активации